1. Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques.
- Author
-
Li, Hongzhao, Hai, Yan, Lim, So-Yon, Toledo, Nikki, Crecente-Campo, Jose, Schalk, Dane, Li, Lin, Omange, Robert W., Dacoba, Tamara G., Liu, Lewis R., Kashem, Mohammad Abul, Wan, Yanmin, Liang, Binhua, Li, Qingsheng, Rakasz, Eva, Schultz-Darken, Nancy, Alonso, Maria J., Plummer, Francis A., Whitney, James B., and Luo, Ma
- Subjects
IMMUNOGLOBULINS ,PROTEOLYTIC enzymes ,T cells ,IMMUNITY ,SEROLOGY - Abstract
HIV mutates rapidly and infects CD4
+ T cells, especially when they are activated. A vaccine targeting conserved, essential viral elements while limiting CD4+ T cell activation could be effective. Learning from natural immunity observed in a group of highly HIV-1 exposed seronegative Kenyan female sex workers, we are testing a novel candidate HIV vaccine targeting the 12 viral protease cleavage sites (PCSs) (the PCS vaccine), in comparison with a vaccine targeting full-length Gag and Env (the Gag/Env vaccine) in a Mauritian cynomolgus macaque/SIV model. In this study we evaluated these vaccines for induction of mucosal antibodies to SIV immunogens at the female genital tract. Bio-Plex and Western blot analyses of cervicovaginal lavage samples showed that both the PCS and Gag/Env vaccines can elicit mucosal IgG antibody responses to SIV immunogens. Significantly higher increase of anti-PCS antibodies was induced by the PCS vaccine than by the Gag/Env vaccine (p<0.0001). The effect of the mucosal antibody responses in protection from repeated low dose pathogenic SIVmac251 challenges is being evaluated. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF